(Q39012031)

English

The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies.

scientific article published on January 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Alain A Vertès

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Regenerative Medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

345-373

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Hematopoietic-cell transplantation at 50.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Graft-versus-leukemia effects of transplantation and donor lymphocytes

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Plasma biomarkers of lower gastrointestinal and liver acute GVHD.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

The best endpoint for acute GVHD treatment trials

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Manufacturing and banking of mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Progress and prospects for engineered T cell therapies

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stromal cells: sensors and switchers of inflammation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal Stem Cells: Mechanisms of Inflammation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cord Blood Transplantation: Can We Make it Better?

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cell therapy and acute graft-versus-host disease: a review

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Allogeneic mesenchymal stem cells: agents of immune modulation.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells: immune evasive, not immune privileged

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Clinical trials for stem cell therapies

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Umbilical cord blood transplantation: the first 25 years and beyond

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

SDF-1 in myocardial repair

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

CXCR4 expression in CD34+ cells and unit predominance after double umbilical cord blood transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

How do stem cells find their way home?

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

L-selectin-mediated lymphocyte rolling on MAdCAM-1.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

E-selectin as a target for drug delivery and molecular imaging.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Human deficiencies of fucosylation and sialylation affecting selectin ligands

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Ex vivo expansion of human hematopoietic stem and progenitor cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Hematopoietic stem cell transplantation: a global perspective

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Chemical approaches to stem cell biology and therapeutics

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cord blood banking and transplantation: advances and controversies

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Concise review: chemical approaches for modulating lineage-specific stem cells and progenitors

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Co-culture of hematopoietic stem cells with mesenchymal stem cells increases VCAM-1-dependent migration of primitive hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Hematopoietic stem cells in co-culture with mesenchymal stromal cells--modeling the niche compartments in vitro.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Ex vivo expansion of cord blood

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Prospective isolation of human MSC.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Adult adherent stromal cells in the management of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stromal cells for graft-versus-host disease

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

MSCs, Macrophages, and Cancer: A Dangerous Ménage-à-Trois

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Pluripotent stem cells in regenerative medicine: challenges and recent progress

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Manipulation of hematopoietic stem cells for regenerative medicine

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Regulatory T cell induction, migration, and function in transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Development and maintenance of regulatory T cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Association of Foxp3 regulatory gene expression with graft-versus-host disease

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Foxp3+-inducible regulatory T cells suppress endothelial activation and leukocyte recruitment

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Natural killer cells: the journey from puzzles in biology to treatment of cancer

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Natural killer cells and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cellular therapy of cancer with natural killer cells-where do we stand?

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Prospects for the use of NK cells in immunotherapy of human cancer.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Determinants of antileukemia effects of allogeneic NK cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells in health and disease

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Multilineage potential of adult human mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

The MSC: an injury drugstore

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells in tissue repair

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stromal cells: new directions.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Multipotent mesenchymal stromal cells and the innate immune system

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

How mesenchymal stem cells interact with tissue immune responses

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells: biology and potential clinical uses

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Stromal cells-are they really useful for GVHD?

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Treatment of graft-versus-host-disease with mesenchymal stromal cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

History of hematopoietic stem cell transplantation: evolution and perspectives

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stromal cells as treatment for chronic GVHD.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

The global landscape of stem cell clinical trials

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Mesenchymal stem cells in the treatment of pediatric diseases

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Regulation, manufacturing and building industry consensus

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Application of MultiStem(®) Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

What matters most in commercial success: first-in-class or best-in-class?

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Cell therapy for autoimmune diseases

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Have we made progress in the treatment of GVHD?

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Discovery and validation of graft-versus-host disease biomarkers

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Micromarrows--three-dimensional coculture of hematopoietic stem cells and mesenchymal stromal cells.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment.

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Targeting inflammation in the treatment of type 2 diabetes: time to start

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow

1 reference

https://api.crossref.org/works/10.2217%2FRME.15.13

21 January 2018

Identifiers

10.2217/RME.15.13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25933242%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39012031&oldid=1622370688"